Evidence map›Paper›PMID 42415662›Full record

ArticleChembiochem : a European journal of chemical biology2026

Hybrid Aminoferrocenes With Nitrate Esters for In Situ Peroxynitrite Generation: Complex Interplay Between Redox Chemistry, NO-Donor Reactivity, and Aminoferrocene Activation Influences In Vitro Anticancer Activity.

Hülya Gizem Özkan, Roman Selin, Paula Holst, Rainer Tietze, Christoph Alexiou, Andriy Mokhir

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hülya Gizem ÖzkanDepartment of Chemistry and Pharmacy, Chair Organic Chemistry II, Friedrich-Alexander University (FAU) of Erlangen-Nürnber, Erlangen, Germany.
Roman SelinDepartment of Chemistry and Pharmacy, Chair Organic Chemistry II, Friedrich-Alexander University (FAU) of Erlangen-Nürnber, Erlangen, Germany.ORCID https://orcid.org/0000-0003-3769-8011
Paula HolstDepartment of Chemistry and Pharmacy, Chair Organic Chemistry II, Friedrich-Alexander University (FAU) of Erlangen-Nürnber, Erlangen, Germany.ORCID https://orcid.org/0009-0000-1713-8418
Rainer TietzeDepartment of Otorhinolaryngology, Head and Neck Surgery, Else Kröner-Fresenius-Foundation-Professorship, Section of Experimental Oncology and Nanomedicine (SEON), University Hospital, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU), Erlangen, Germany.
Christoph AlexiouDepartment of Otorhinolaryngology, Head and Neck Surgery, Else Kröner-Fresenius-Foundation-Professorship, Section of Experimental Oncology and Nanomedicine (SEON), University Hospital, Friedrich-Alexander-University of Erlangen-Nürnberg (FAU), Erlangen, Germany.ORCID https://orcid.org/0000-0003-2220-6790
Andriy MokhirDepartment of Chemistry and Pharmacy, Chair Organic Chemistry II, Friedrich-Alexander University (FAU) of Erlangen-Nürnber, Erlangen, Germany.ORCID https://orcid.org/0000-0002-9079-5569

Funding

Alexander von Humboldt-Stiftung Philipp Schwartz Initiative for a fellowship for RSHorizon 2020 Framework FET Open: 861878,
6 · The paper itself

Abstract

Aminoferrocene-based prodrugs represent a promising class of redox-active anticancer agents that can be selectively activated in oxidative cellular environments. However, activation of these systems typically relies on reactive oxygen species (ROS) and is therefore inefficient in intracellular compartments with low ROS levels, such as the cytoplasm. In this study, we explored strategies to enhance activation of organelle-non-biased aminoferrocene prodrugs through peroxynitrite (ONOO

Indexed as

Antineoplastic AgentsEstersFerrous CompoundsMetallocenesNitratesNitric Oxide DonorsPeroxynitrous AcidProdrugsCell Line, TumorHumansMolsidomineOxidation-ReductionReactive Oxygen SpeciesAntineoplastic AgentsEstersferroceneFerrous CompoundslinsidomineMetallocenesMolsidomineNitratesNitric Oxide DonorsPeroxynitrous AcidProdrugsReactive Oxygen Speciesaminoferrocenecancernitrate esterprodrugreactive oxygen species

Identifiers

PMID42415662
PMCPMC13343212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.